BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31989786)

  • 21. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
    Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
    Oncologist; 2013; 18(5):600-10. PubMed ID: 23635558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.
    Youn B; Wilson IB; Mor V; Trikalinos NA; Dahabreh IJ
    Health Serv Res; 2021 Jun; 56(3):486-496. PubMed ID: 33682120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
    Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
    J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
    Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
    Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
    Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
    PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer.
    Goulart BH; Reyes CM; Fedorenko CR; Mummy DG; Satram-Hoang S; Koepl LM; Blough DK; Ramsey SD
    J Oncol Pract; 2013 Jan; 9(1):42-50. PubMed ID: 23633970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
    PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physician variation in lung cancer treatment at the end of life.
    Green JB; Shapiro MF; Ettner SL; Malin J; Ang A; Wong MD
    Am J Manag Care; 2017 Apr; 23(4):216-223. PubMed ID: 28554208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race and sex differences in the receipt of timely and appropriate lung cancer treatment.
    Shugarman LR; Mack K; Sorbero ME; Tian H; Jain AK; Ashwood JS; Asch SM
    Med Care; 2009 Jul; 47(7):774-81. PubMed ID: 19536007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
    Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
    Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
    Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
    Ramsey SD; Howlader N; Etzioni RD; Donato B
    J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the use of evidence-based therapy for resectable gastric cancer.
    Snyder RA; Penson DF; Ni S; Koyama T; Merchant NB
    J Surg Oncol; 2014 Sep; 110(3):285-90. PubMed ID: 24891231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer.
    Younes RN; Pereira JR; Fares AL; Gross JL
    Rev Assoc Med Bras (1992); 2011; 57(6):686-91. PubMed ID: 22249550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
    Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
    [No Abstract]   [Full Text] [Related]  

  • 39. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disparities in Systemic Treatment Use in Advanced-stage Non-Small Cell Lung Cancer by Source of Health Insurance.
    Maguire FB; Morris CR; Parikh-Patel A; Cress RD; Keegan THM; Li CS; Lin PS; Kizer KW
    Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1059-1066. PubMed ID: 30842132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.